TRZ

Synthetic peptide analog (tirzepatide) studied for its ability to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Known in the scientific literature as a dual incretin receptor agonist, it has been widely researched for its role in metabolic signaling pathways, energy balance studies, and endocrine-related mechanisms. GIP receptor activation influences cAMP/PKA signaling, insulin secretion in model systems, beta-cell function, and energy-balance pathways. GLP-1 receptor activation involves gastric emptying, hypothalamic appetite circuits, and glucagon modulation.

Supplied to verified B2B accounts only — research institutions under RUO, or licensed 503A compounding pharmacies as API. Not FDA-approved for human or veterinary therapeutic use. See the disclaimer.